DIO1: A Drug Target / Disease Biomarker (G1733)

Target Name: DIO1

NCBI ID: G1733

DIO1

DIO1: A Drug Target / Disease Biomarker

DIO1, also known as doublecortin, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of DIO1 is its role in the regulation of stem cell proliferation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body, and are a key factor in the development and repair of tissues. DIO1 plays a critical role in regulating the stem cell pool by controlling the number of stem cells that are produced and by regulating their differentiation into different cell types.

In addition to its role in stem cell biology, DIO1 is also involved in the regulation of cell survival and lifespan. It has been shown to play a key role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. DIO1 has been shown to promote apoptosis in a variety of cell types, including cancer cells, and may contribute to the development and progression of cancer.

DIO1 has also been implicated in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases. DIO1 has been shown to be involved in the development and progression of neurodegenerative diseases by regulating the production of glial cells, which are a type of nerve cell that support the growth and survival of other neurons.

In addition to its role in neurodegenerative diseases, DIO1 has also been implicated in the development and progression of autoimmune disorders. These conditions are characterized by the immune system attacking the body's own tissues and causing inflammation and damage. DIO1 has been shown to play a key role in the regulation of immune cell function and has been implicated in the development of autoimmune disorders by regulating the production of immune cells.

DIO1 is also a potential drug target for a variety of diseases. For example, DIO1 has been shown to be involved in the development and progression of cancer by regulating the production of stem cells and promoting apoptosis. As a result, DIO1 may be a useful target for cancer therapies that aim to inhibit stem cell proliferation or promote apoptosis. In addition, DIO1 has been shown to be involved in the regulation of neurodegenerative diseases, and may be a useful target for therapies aimed at treating these conditions.

Overall, DIO1 is a protein that has important roles in regulating cell proliferation and differentiation, and is implicated in a number of diseases. Further research is needed to fully understand its functions and potential as a drug target.

Protein Name: Iodothyronine Deiodinase 1

Functions: Responsible for the deiodination of T4 (3,5,3',5'-tetraiodothyronine) into T3 (3,5,3'-triiodothyronine) and of T3 into T2 (3,3'-diiodothyronine). Plays a role in providing a source of plasma T3 by deiodination of T4 in peripheral tissues such as liver and kidney

The "DIO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets